CURRICULUUM VITAE
PROF. MONICA BOCCHIA
Nata a Parma il 7/8/63
TITOLI DI STUDIO

Laurea con Lode in Medicina e Chirurgia l’Università degli Studi di Parma, Luglio 1988.

Diploma di Specializzazione con Lode in Ematologia Clinica e di Laboratorio, Università degli Studi
di Bologna nel Giugno 1991.

United States Medical Licensing Examination STEP 1 (basic biomedical science) e STEP 2 (clinical
science) New York, USA 1994.

Educational Commission for Foreign medical graduates English Test, New York, USA 1994

Nomina a Professore Associato di Ematologia, Università degli Studi di Siena, Novembre 2002
BORSE DI STUDIO

Borsa di Studio Lotta all’AIDS indetta dall’Istituto Superiore della Sanità per l’anno Accademico
1991-1992
ATTIVITA’ SVOLTA ALL’ESTERO

Research Fellow e Research Associate presso l’Hematopoietic Cancer Immunochemistry Laboratory
del Memorial Sloan-Kettering Cancer Center di New York U.S.A. dal Settembre 1992 al Giugno 96.
ESPERIENZA LAVORATIVA IN ITALIA

Dirigente di I livello presso la Cattedra e Divisione di Ematologia dell’ Azienda Ospedaliera Senese
dal 1/1/97 al 28/10/2002.

Professore Associato di Ematologia nel Dipartimento di Medicina Clinica e Scienze Immunologiche
con attività assistenziale dal Novembre 2002-oggi.
INCARICHI





Direttore f.f. U.O.C. Ematologia Azienda Ospedaliera Universitaria Senese dal 1/02/2012 ad oggi
Responsabile Ambulatorio e Day Hospital della U.O.C. di Ematologia e Trapianti (dal 2010 UOC di
Ematologia) , Azienda Ospedaliera Universitaria Senese dal 1997 al Giugno
Inacarico IP3 “Responsabile del DAY Hospital e del Laboratorio di immunoterapia” UOC
Ematologia dal luglio 2011.
Responsabile del Laboratorio di Immunoterapia della U.O.C. di Ematologia e Trapianti (dal 2010
UOC di Ematologia) , Azienda Ospedaliera Universitaria Senese dal gennaio 2002 ad oggi.
Professore di Ematologia in
- Corso Integrato di Patologia Medica, Facoltà di Medicina e Chirurgia, Università di Siena
dal 2002 ad oggi
- Scuola di Specializzazione in Ematologia, Università di Siena dal 1998 ad oggi
- Corso di Biotecnologia in Medicina Interna, Laurea Interfacoltà di Biotecnologie dal 2002 al
2010.
- Laurea Infermieristica, Università di Siena dal 2008 al 2010
- Laurea breve Tecnici Perfusionisti , Università di Siena dal 2008 ad oggi
- Laurea Magistrale in Biotecnologia dal 2012 ad oggi
- Scuola di Specializzazione in Chirurgia Toracica, Cardiochirurgia, Microbiologia,
Dermatologia, Malattie Infettive dal 2012 ad oggi
PRINCIPALE ATTIVITA’ DI RICERCA
 Sviluppo di anticorpi monoclonali diretti contro IgM di superficie lo sviluppo di immunoterapia
passive nei linfomi non Hodgkin B
 Sviluppo di anticorpi monoclonali contro i prodotti precoci dell’Aspergillo Fumigatus per uso
diagnostico e terapeutico
 Sviluppo di modelli murini di vaccinoterapia anti-idiotipo per il trattamento del Mieloma Multiplo e
il linfoma non Hodgkin
 Sviluppo di vaccini peptidici derivati dal bcr-abl per il trattamento immunomediato specifico attivo
della Leucemia Mieloide Cronica
 Sviluppo di una strategia di vaccinoterapia peptidica anti p190 nella leucemia acuta linfoblastica
Philadelphia positiva
 Assetto immunologico funzionale dei pazienti affetti da leucemia mieloide cronica
 Caratterizzazione funzionale antitumorale della risposta linfocitari T indotta in vivo da vaccini
peptidici
 Ideazione, sviluppo e implementazione di studi clinici sperimentali di vaccinoterapia peptidica nella
leucemia mieloide cronica




Sviluppo di vaccine peptidici derivati dal WT1 per la leucemia mieloide acuta e le Sindromi
Mielodisplastiche
Valutazione di cellule staminali residue durante la terapia con inibitori delle tirosino chinasi
Caratterizzazione della cellula staminale leucemica nella leucemia mieloide acuta
Caratterizzazione molecolare dei fattori pro-trombotici nei pazienti affetti da Leucemia
Mileoide Cronica in trattamento con TKIs.
MEMBERSHIP
 SIE (Società Italiana di Ematologia) dal 2003-oggi
 SIES (Società Italiana di Ematologia Sperimentale) dal 1994-oggi


ELN (Eureopean Leukemia Net) dal 2011 ad oggi
Revisore per Blood Journal, Leukemia, Haematologica
CONFERENZE SU INVITO E SEMINARI (SELEZIONATI)


















45° ASH Annual Meeting, S.Diego USA, Dec. 2003
International Workshop on Cancer Vaccines, University of Siena, Nov 2004
European Investigators on Chronic Myeloid Leukemia, Oxford UK, May 2005
European Working Group on CML 10th EHA Meeting, Stockholm, SW, June 2005
47th ASH Annual Meeting, Atlanta, USA, Dec 2005
Evolving concept in the management of CML, ELN, Venice, May 2006
IX SIES Conference Naples 2006
DGHO Leipzig, Germany Nov 2006
Nordic CML Symposium Helsinky Oct 2006
CML Prospect for the 21st century. European School of Hematology Mandelieu, France Sept
New Castle CML Meeeting, New Castle, UK Nov 2007
Patients Conference CML Meeting, Edimburgh, Scotland Nov 2007
18th International CML Workshop, Mannehim Jun 2009
ELN Meeting Barcelona Sept 2009
51st ASH Meeting New Orleans Dec 2009
6th Nilotinib global Investigator Meeting, Roma Apr 2010
EI-CML (European Investigator Meeting on CML) Spineto, May 2010
24th Annual Meeting of the Czech Society of Hematology, Olomouc June 2010






“Nilotinib and Immunotherapy” Advisory Board Meeting, New York July 2010
-Turkish Society of Cellular Therapy and Regenerative Medicine, Izmir Turchia, Feb 2011
-EI-CML (European Investigator Meeting on CML) Praga, Ceck Rep, May 2011
43° SIE Conference Napoli Oct 2011
-Nilotinib Global Investigator meeting , Bordeaux Oct 2012
-XII SIES Conference 2012 Rome Oct 2012
PROGETTI FINANZIATI



Co-Principal Investigator: NIH RO1 CA55349 (1994); NIH PO1 CA64593 (1995)
Principal Investigator:
o PRIN 2003: Gene immunotherapy in Chronic Myeloid Leukemia: development and
use of DNA vaccines
o PAR 2003 : Vaccination with P210-derived multipeptides vaccine: clinical and
immunological evaluation in Chronic Myeloid Leukemia (CML) patients with
minimal residual disease
o FONDAZIONE MONTE DEI PASCHI 2003: development of a DNA vaccines
for the control of minimal residual disease in Chronic Myeloid Leukemia.
o PRIN 2005 : Immunotherapeutic approach for minimal residual disease CML:
development and clinical use of a P210 b2a2 derived peptide vaccine
o PAR 2005: Immunotherapeutic approach for minimal residual disease in chronic
myeloid leukemia: development and clinical use of a P210 b2a2 derived peptide
vaccine
Coordinatore Nazionale:
o PRIN 2008 : Development of a WT-1 derived peptide vaccine as immune mediated
targeted therapy for the control of minimal residual disease in
acute myeloid leukemia
PUBBLICAZIONI

Coautore di 119 Pubblicazioni a Stampa (Impatto totale 600)

Coautore di 115 Abstracts.

H-Index 23
BREVETTI (a valenza USA-EUROPA)

·“Oncogene fusion protein peptide vaccines”

“Aspergillus Fumigatus lectin and methods of using same”
Siena, 21/03/2013
ELENCO PUBBLICAZIONI A STAMPA
1)
Mazza P, Zinzani PL, Gherlinzoni F, Bocchia M, Vianelli N, Miggiano MC, Zanchini R,
Barbieri E, Frezza P, Sciascia R, Neri S, Miniaci G, Pileri S, Poletti G, Dominici G, Altini E, Tura
S. A critical valuation of prognostic analysis in high grade non-Hodgkins' lymphomas. Acta
Oncologica X-n.4/89. (Impact Factor =0.895).
2)
Lauria F, Zinzani PL, Raspadori D, Foa R, Buzzi M, Gugliotta L, Bocchia M, Benfenati D,
Tura S. Relationship between immunological response to alpha-IFN treatment in 35 patients with
hairy cell leukemia. Eur J Haematol 45 (Suppl 52):3-6. 1990.(IF=1.852)
3)
Zinzani PL, Mazza P, Gherlinzoni F, Zanchini R, Bocchia M, Aitini E, Cavazzini G, Amurri
B, Gobbi M, Tura S. CEOP regimen in the treatment of advanced low-grade non Hodgkin’s
lymphomas: a preliminary report. Tumori, 76:533-6, 1990.(IF= 1.852)
4)
Mazza P, Tura S, Bocchia M, Zinzani PL, Gherlinzoni F, Mandelli F, Anselmo MP, Papa G,
Antimi M, Gobbi PG, Porcellini A, Rizzoli V, Resegotti L, Levis A, Deriu L, Chiericini A, Ciccone
F, Fannin R, Castoldi G, Scapoli GL, Liso V, Chisesi T, Rancan L, Amurri B. Alpha-2b
recombinant interferon (Intron) in Hodgkins' lymphoma: Therapeutic perspective. Eur I Haematol
45 (Suppl 52):22-24. 1990.(IF= 1.852)
5)
Mazza P, Bocchia M, Zinzani PL, Gherlinzoni F, Raspadori D, Buzzi M. Alpha-interferon
in Hodgkins' lymphoma. J of Chemother (Suppl 2). 1990.(IF= 0.865)
6)
Mazza P, Bocchia M, Zinzani PL, Gherlinzoni F, Ghetti PL. Rational basis for the use of
alpha 2A interferon in the treatment of mycosis fungoides. Haemaologica 1990. 75 (Suppl 4): 7881.(IF=3.216)
7)
Mazza P, Papa G, Zinzani PL, Vegna ML, Bocchia M, Simoni R, Zanchini R, Gherlinzoni
F, Poletti G, Ghetti PL, Tura S, Mandelli F. Interferone nelle micosi fungoide. XVI Corso
Nazionale de Aggiornamnto in Ematologia Clinica Societa’ Editrice Esculapio, 1990.
8)
Zinzani PL, Lauria F, Buzzi M, Raspardori D, Gugliotta L, Bocchia M, Macchi S, Algeri R,
Tura S. Hairy cell leukemia variant: A morphologic, immunologic and clinical study of 7 cases.
Haematologica 75:54-57. 1990.(IF= 3.216)
9)
Bocchia M, Zaccaria A, Mazza P, Tura S. La prevenzione della nausea e del vomito nel
paziente ematologico con i 5-HT3 antagonisti. Atti del Congresso IL trattamento della nausea e del
vomito da chemioterapia antineoplastica: nuove acquisizioni sul ruolo dei 5HT3 antagnoista.
Verona, 18 Giugno 1991.
10)
Zinzani PL, Lauria F, Raspadori D, Buzzi M, Benfenati D, Bocchia M, Rondelli D, Tura S.
Comparison of low-dose versus standard-dose alpha-interferon regimen in the hairy cell leukemia
treatment. Acta Haematol 85:16-19. 1991.(IF=1.195)
11)
Zinzani PL, Mazza P, Gherlinzoni F, Zanchini R, Bocchia M, Tura S. Mycosis Fungoides:
A therapeutical review. Haematologica 1991. 76:150-161.(IF= 3.216)
12)
Gherlinzoni F, Mazza P, Bocchia M, Zinzani PL, Fiacchini M, Zanchini R, Pileri S, Tura S.
Stage I high-grade non-Hodgkins' lymphomas: a retrospective analysis. Haematoogica 1991.
76:38-42. (IF= 3.216)
13)
Mazza P, Bocchia M, Zanchini R, Gherlinzoni F, Zinzani PL, Pileri S, Tura S. MN
(N=Novatrone) COP-B therapy on higher and intermediated grade non-Hodgkins' lymphoma: An
alternative to MA (A=Adriamycin) COP-B. Haematologica 76:47-52. 1991.(IF= 3.216)
14)
Zinzani PL. Fiacchini M, Mazza P, Gherlinzoni F, Bocchia M, Tura S. Fifteen year
experience in Hodgkins' Disease: Role of combined modality treatment and splenectomy in the
incidence of secondary acute leukemia. Haematologica 76:305-310, 1991.(IF= 3.216)
15)
Zinzani PL, Pileri S, Mazza P, Gherlinzoni F, Bocchia M, Poletti G, Sabattini E, Poggi S,
Tura S. Primary malignant Lymphoma of the testis. Clinico-pathologic study of 9 cases. Acta
Onc. 12:293-296, 1991. (IF 0,895)
16)
Tura S, Mandelli F, Mazza P, Pileri S, Gherlinzoni F, Bocchia M, Zinzani PL, Fiacchini M,
Martelli M, Papa G. et al. MACOP-B vs F-MACHOP in the treatment of non-Hodgkin’s
lymphomas. Leukemia 1:74-8, 1991 (IF 2.945)
17)
Mazza P, Bocchia M, Tura S, Tumietto F, Costigliola P, Coronado O, Ricchi E, Chiodo F.
Evidence of beneficial effect of recombinant interleukin-2 in HIV-associated lymphoma. AIDS
5:1141-1142, 1992. (IF= 8.018)
18)
Mazza P, Bocchia M, Tumietto F, Costigliola P, Coronado O, Bandini G, Conte R, Ricchi E,
Vianelli N, Raise E, Fondacara A, Re MC, Vignoli M, Chiodo F, Tura S. Recombinant
Interleukin-2 (IL-2) in Acquired Immune Deficiency Syndrome (AIDS): Preliminary report in
patients with lymphoma associated to HIV infection. Eur J Haemat. 49:1-6, 1992. (IF= 1.852)
19)
Zinzani PL, MazzaP, Gherlinzoni F, Bocchia M, Fiacchini M, Bendandi M, Barbieri E,
Frezza G, Neri S, Aitini E et al. Massive mediastinal involvment in stage I-II Hodgkin’s disease:
response to combined modality treatment. Leukemia and Lymphoma 8:81-5, 1992. (IF= 1.140)
20)
Zinzani PL, Mazza P, Gherlinzoni F, Bocchia M, Bendandi M, Fiacchini M, Tura s. “Very
late” relapses in Hodgkin’s disease patients: a rare but real phenomenon. Haematologica 77:435-7,
1992.
(IF= 3.216)
21)
Mazza P, Bocchia M, Zinzani PL, Fiacchini M, Gherlinzoni F, Bandini G, Bendandi M,
Frezza GP, Neri S, Barbieri E et al. Hodgkin’s disease: summary of twenty years of experience.
Haematologica 77:487-93, 1992. (IF= 3.216)
22)
Pileri S, Poggi S, Sabattini E, Benni M, Melilli G, Santucci MA, Gherlinzoni F, Falini B,
Bocchia M, Leoncini L, Tosi P. Apoptosi: un programma di morte per la vita cellulare. XVIII
Corso Nazionale di Aggiornamento in Ematologia Clinica Societa’ Editrice Esculapio, 1993.
23)
Zinzani PL, Lauria F, Rondelli D, Benfenati D, Raspadori D, Bocchia M, Bendandi M, Zaja
F, Fanin R, Russo D, Galieni P, Tura S. Fludarabine: An active agent in the treatment of
previously treated and untreated low grade non-Hodgkin's lymphoma. Annals of Oncology. 4:5758, 1993. (IF= 2.736)
24)
Zinzani PL, Lauria F, Rondelli D, Benfenati D, Raspadori D, Bocchia M, Cavo M, Cirio
TM, Zaja F, Russo D, Fanin R, Galieni P, Algeri R, Tura S. Fludarabine in patients with advanced
and/or resistant B-chronic lymphocytic leukemia. Europ J Haematol. 51:93-7. 1993. (IF= 1.852)
25)
Pileri S, Falini B, Poggi S, Benni M, Bocchia M, Melilli G, Sabattini E, Tazzari PL, Stein H.
Consideration in Hodgkin’s disease. Pathologica 85:445-66, 1993. (IF= 0.838)
26)
Pileri S, Bocchia M, Baroni CD, Martelli M, Falini B, Sabattini E, Gherlinzoni F, Amadori
S, Poggi S, Mazza P et al. Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective
clinico-pathological study of 69 cases. Br J Haematol 86:513-23, 1994. (IF= 3.065)
27)
Mazza P, Zinzani PL, Martelli M, Fiacchini M, Bocchia M, Pileri S, Falini B, Martelli MF,
Amadori S, Papa G. MACOP-B versus F-MACHOP regimen in the treatment of high grade NonHodgkin’s Lymphomas. Leuk and Lymph 16: 457-463, 1995. (IF= 1.140)
28)
Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A.
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood
85:2680-268, 1995 (IF= 10.12)
29)
Nikula KT, Bocchia M, Curcio MJ, Sgouros G, Ma Y, Finn RD, Scheinberg Da. Impact of
the high tyrosin fraction in complementarity determining regions: measured and predicted effects of
radioiodination on IgG immunoreactivity. Mol. Immunol 32:865-872, 1995 (IF=2.023)
30)
Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific
human cellular immunity to bcr-abl oncogene derived peptides. Blood, 87: 3587-3592, 1996 (IF=
10.12)
31)
Bocchia M, Korontsvit T, Xu Q, Schienberg DA, Lauria F. Vaccinoterapia antitumorale: il
modello della leucemia mieloide cronica. XXI Corso Nazionale di Aggiornamento in Ematologia
Clinica Societa’ Editrice Esculapio. 133-135, 1997
32)
LauriaF, Rondelli D, Zinzani PL, Bocchia M, Marotta G, Salvucci M, Raspadori D, Ventura
MA, Birtolo S, Forconi F and Tura S. Long-lasting complete remission in patients with hairy cell
leukemia trated with 2-CdA: a 5-year survey. Leukemia 11: 629-632, 1997 (IF=2.945)
33)
Bocchia M, Xu Q, Whelsey U, Xu Y, Korontsvit T, Loganzo F, Albino A, Scheinberg DA.
Modulation of p53, WAF1/p21 and bcl-2 expression during Retinoic Acid-induced differentiation
of NB4 promyelocitic cells. Leuk Res, 21:139-147, 1997 (IF= 1.423)
34)
Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D : Weekly
administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia : a new treatment
schedule effective and safer in preventing infective complications. Blood 89: 1838-1839, 1997.
(IF= 10.12)
35)
36)
Marotta G, Bucalossi A, Galieni P, Bigazzi C, Nuti S, Valenzin E, Bocchia M, Lauria F.
CD4+/CD45RA+ “naive” T cells and immunological response to influenza virus vaccine in B-cell
chromnic lymphocitic leukemia patients. Acta Haematol. 99: 18-21, 1998 (IF=1.195)
Zinzani PL, Martelli M, Magagnoli M, Zaccaria A, Ronconi F, Cantonetti M, Bocchia M,
Marra R, Gobbi M, Falini B, Gherlinzoni F, Moretti L, De Renzo A, Mazza P, Pavone E, Sabattini
E, Amendola A, Bendandi M, Pileri SA, Mandelli F, Tura S. Anaplastic large lymphoma
Hodgkin’s-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy.
Blood 92:790-794, 1998 (IF= 10.12)
37)
Marotta G, Bigazzi C, Bocchia M, Forconi F, Lauria F. Long-term follow up of nonHodgkin’s lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the
intermediate grade subtype. Haematologica 83:852-864, 1998 (IF=3.216)
38)
Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly
administration of 2-Chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and
reduces infectious complications. Haematologica 84: 22-25, 1999 (IF=3.216)
39)
Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni
G, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F,
Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S. Elderly aggressivehistology non-Hodgkin lymphoma: first line VNCOP-B regimen experience on 350 patients. Blood
94:33-38, 1999. (IF= 10.12)
40)
Bocchia M, Bigazzi C, Marconcini S, Forconi F, Marotta G, Algeri R, Lauria F. Favorable
impact of low dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment
for low-grade non Hodgkin’s lymphomas. Hematologica 84:716-720, 1999.(IF=3.216)
41)
Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M, Bucalossi A, Marotta G,
Tozzi M, Lauria F. Fludarabine containing-regimens may adversely affect peripheral blood stem
cell collection in low-grade non-Hodgkin lymphoma patients. Leukemia and Lymphoma 1999.
37:157-61. (IF=1.140)
42)
Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo
Amalia, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M,
Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S. How do patients with aggressive nonHodgkin lymphoma’s treated with third generation regimens fare in the long term? Haematologica
84:996-1001, 1999. (IF=3.216)
43)
Zinzani PL, Magagnoli M, Moretti L, Battista R, Ronconi F, De Renzo A, Zaccaria A,
Gentilini P, Guardigni L, Gherlinzoni F, Cellini C, Fattori PP, Bendandi M, Bocchia M, Aitini E,
Tura S. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging
experience in 29 patients. Haematologica 84:1002-1006, 1999. (IF=3.216)
44)
Forconi F, Bocchia M, Marconcini S, Bigazzi C, Milani Marina, Fraternali-Orcioni G,
Lauria F. CD30 positive (non-anaplastic) peripheral T cell lymphoma of the thyroid gland.
Haematologica 84:946-948, 1999. (IF=3.216)
45)
Pinilla –Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L,
Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia
with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95:
1781-1787, 2000. (IF= 10.12)
46)
Lauria F, Bigazzi C, Birtolo S, Bocchia M, Bucalossi A, Forconi F, Marotta G. Alchilanti e
Tiopurine nelle oncoemopatie. Il pensiero scientifico Editore, Marzo 2000.
47)
Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L,
Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S. Antitumor vaccination: where we stand.
Haematologica 85:1172-1206, 2000. (IF=3.216)
48)
Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F. Low-dose fludarabine and
cyclophosohamide in elderly patients with B-cell chronic lymphocytic leukemia refractory in
conventional theraphy. Haematologica, 85:1268-1270, 2000. (IF=3.216)
49)
Zinzani PL, Martelli M, Bendandi M, De Renzo A, Zaccaria A, Pavone E, Bocchia M,
Falini B, Gobbi M, Gherlinzoni F, Stefoni V, Tani M, Tura S. Primary mediastinal large-B cell
lymphoma with sclerosis: a clinica study of 89 patients treated with MACOP-B chemotherapy and
radiation therapy. Haematologica 86:187-191, 2001. (IF=3.216)
50)
Bocchia M, Tozzi M, Lauria F. Casi Pro Diagnosi in Oncologia ed Ematologia. Pag. 45-50.
2001.
51)
Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S,
La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foà R. Efficacy of anti-CD20
antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica, 86:10461051, 2001. (IF=3.216)
52)
Bocchia M, Gentili S, Lauria F. Is there any role left for p210-derived peptide vaccines in
chronic myeloid leukemia? Haematologica, 87:675-677, 2002. (IF=3.216)
53)
Bocchia M, Gentili S, Forconi F, Lenoci M, Tozzi M, Lauria F. Low-grade non Hodgkin’s
lymphomas (LG-NHL) in the elderly: impact of a low-dose fludarabine based combination regimen
(mini-FLEC). Haematologica, 2003. 88:358-360. (IF=3.216)
54)
Sammassimo S, Mazzotta S, Tozzi M, Gentili S, Lenoci M, Bucalossi A, Bocchia M e
Lauria F. Disseminated mucormucosis in a patient with acute myeloblastic leukemia misdiagnosed
as infection by Enterococcus faecium. J Clin Microbiol. 42:487-489, 200. (IF=3.320)
55)
Gozzetti A, Tozzuoli D, Crupi R, Gentili S, Bocchia M, Raspadori D, Lauria F. Emergence
of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic
remission after therapy with imatinib mesylate (STI). Eur J Haematol 71:313-314, 2003.
(IF=1.852)
56)
Gozzetti A, Tozzuoli D, Crupi Rosaria, Fanelli albertina, Gentili Sara, Bocchia M, Mazzotta
Serena, Raspadori Donatella, Lauria Francesco. A novel t(6;7)(p24;q21) in a chronic myelocytic
leukemia patient in complete cytogenetic remission after therapy with imatinib mesylate. Cancer
genetics and Cytogenetics, 2003. (IF=1.542)
57)
Gozzetti A, Tozzuoli D, Crupi R, Bocchia M, Mazzotta S, Lauria F. Effect of 5637
conditioned medium (CM) on the mitotic index in the cytogenetic evaluation of myeloproliferative
disorders. Ann Genet. 47(4):432-4, 2004. (IF=2.307)
58)
Gozzetti A, Tozzuoli D, Crupi R, Bocchia M, Mazzotta S, Raspadori D, Lauria F A case of
i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia. Cancer
Genet Cytogenet. 154:193-4, 2004. (IF=1.542)
59)
Bocchia M, Gentili S, Abruzzese E*, Fanelli A, Iuliano F**, Tabilio A°, Amabile M°°,
Forconi F, Gozzetti A, Raspadori D, Lauria F. Effect of a P210 multipeptide vaccine associated
with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual
disease: a multicentre observational trial. Lancet. 365:657-62, 2005. (IF=25.012)
60)
Pirrotta MT, Bucalossi A, Forconi F, Bocchia M, Mazzotta S, Sammassimo S, Gozzetti A,
Lauria F. Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma.
Oncologist. 10:299-300, 2005. (IF=3.962)
61)
Gozzetti A, Crupi R, Tozzuoli D, Fabbri A, Bocchia M, Lauria F. Trisomy 13 in a patient
with idiopathic myelofibrosis. Cancer Genet Cytogenet. 156:185, 2005. (IF=1.542)
62)
Malagola M, Martinelli G, Rondoni, Paolini S, Gaitani S, Arpinati M, Piccaluga PP,
Amabile M, Basi C, Ottaviani E, Candoni A, Gottardi E, Cilloni D, Bocchia M, Saglio Giuseppe,
Lauria F, Fanin R, Visani G, Marrè MC, Maderna M, Rancati F, Vinaccia V, Russo D, Baccarani
M..Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real
target? Blood. 105:904, 2005. (IF=10.12)
63)
Pirrotta MT, Bucalossi A, Forconi F, Gozzetti A, Bocchia M, Mazzotta S, Sammassimo S,
Lauria F. Massive intravascular hemolysis: a fatal complication of Clostridium perfrigens in a
patient with acute lymphoblastic leukemia. Leuk and Lymph. 46:793, 2005. (IF=1.163)
64)
Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D,
Candoni A, Michielucchi A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P,
Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani
G, Fanin R, Baccarani M. Multicenter phase III trial on fludarabine, ARA-C, and idarubicine
(FLAI) versus idarubicine, ARA-C and etoposide (ICE) for induction treatment of younger newly
diagnosed acute myeloid leukemia patients. BJH. 131(2): 172-179, 2005. (IF=3.267)
65)
Mazzotta S, Gozzetti A, Pirrotta MT, Bocchia M, Sammassimo S, Bucalossi A, Lauria F.
Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.
Leukemia & Lymphoma. 46(12): 1837-1838, 2005
(IF=1.163)
66)
Bocchia M, Abruzzese E, Forconi F, Ippoliti M, Trawinnska MM, Pirrotta MT, Raspadori
D, Tozzi M, Gozzetti A, Lauria F. Imatinib does not impair specific antitumor T-cell immunity in
patients with chronic myeloid leukemia . Leukemia 2006 20:142-143. (IF=5.810)
67)
Gozzetti A, Calabrese S, Crupi R, Tozzuoli D, Bocchia M, Fabbri A, Pirrotta MT,
Sammassimo S, Defina M, Lauria F. Trisomy 22 as sole cytogenetic abnormality in acute
monoblastic leucemia (M5b). Cancer Genet. Cytogenet. 2006 Aug 169:86. (IF=1.542)
68)
Bocchia M, Forconi F and Lauria F. Emerging drugs in Chronic Myleoid Leukemia, Expert
Opinion on emerging drugs. 2006; 11 (4): 651-664
69)
Mazzotta S, Guerranti R, Gozzetti A, Bucalossi A, Bocchia M, Sammassimo S, Petralia I,
Ogueli IG, Lauria F. Increase of serum lactate dehydrogenase isoenzymes in ph- Chronic
myeloproliferative diseases: a metabolic adaptation? Hematology 2006, 11(4): 239-44 (IF= 0,8)
70)
Bocchia M and Lauria F. Immunotherapy in Chronic Myeloid Leukemia. Edit J.Cortes and
M Deineger. Informa Healthcare 2006.
71)
Gozzetti A, Crupi R, Tozzuoli D, Calabrese S, Bocchia M, Pirrotta MT, Raspadori D, and
Lauria F. Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission.
Cancer Genet Cytogenet, Jun 2006; 167 (2): 182. (IF=1,542)
72)
Malagola M, Damiani D, Martinelli G, Michelutti A, Cesana B, de Vivo A, Piccaluga PP,
Ottaviani E, Candoni A, Geronim A, Tiribelli M, Fanin R, Testoni N, Lauria F, Bocchia M, Gobbi
M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Piccolo G, Gugliotta L, Bovini, Visani G, Skert C,
Gergonzi C, Roccaro AM, Fili C, Baccarani M, Russo D. Case-control study of multidrug resistance
phenotype and response to induction treatment includine or not fludarabine in newly diagnosed
acute myeloid leukemia patients. Br J Haematol 2007; 136 (1):87-95. (IF.4.492)
73)
Pirrotta MT, Bocchia M, Bucalossi A, Defina M, Forconi F, Gozzetti A, Lauria F. Pilot
study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen
(GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute
myeloid leukemia patients. Acta Haematologica 2007; 118 (1):7-9.
(IF= 0.8 )
74)
Gozzetti A, Bocchia M, Crupi R, Calabrese S, Pirrotta MT, Raspadori D, Defina M, Algeri
R, Lauria F. Concomitant chronic myeloid leukemia and chronic lymphocytic leukemia: a different
clonal origin shown by molecular cytogentics. Cancer Genet Cytogenet 2008; 180 (1):83-84. (IF
1,564).
75)
Gozzetti A, Bocchia M, Calabrese S, Pirrotta MT, Crupi R, Raspadori D, Lauria F.
Promyelocytic blast crisis of chronic myelogenous leukaemia during imatinib treatment. Acta
Haematol 2007; 117 (4):236-237. (IF 1,564)
76)
Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M, Pirrotta MT,
Crupi R, Tozzuoli D, Trawinska MM, Defina M, Martinelli G, Lauria F. CD34+/Ph+ cells are still
detectable in chronic myeloid leukaemia patients with sustained and prolonged complete
cytogenetic remission during treatment with imatinib mesylate Leukemia 2007; 22: 426-428. (IF 6,
146)
77)
Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, Defina M, Bosi A,
Francesco L. Insight into JAK-2V617F mutation in CML. Lancet Oncology 2007; 8(10):864-866.
(IF10,12)
78)
Gozzetti A, Fabbri A, Lazzi S, Bocchia M, Lauria F. Rituximab activity in CD20 positive
multiple myeloma. Leukemia 2007; 21 (8): 1842-3. (IF 6,146)
79)
Gozzetti A, Calabrese S, Raspadori D, Crupi R, Tassi M, Bocchia M, Fabbri A, Lauria F.
Concomitant t(4;11) and t(1;19) in a patient with biphenotypic acute leukemia. Cancer Genet
Cytogenet 2007; 177 (1): 81-2. (IF 1,544)
80)
Gozzetti A, Fabbri A, Lazzi S, Bocchia M, Lauria F. Reply to “Rituximab activity in CD20positive multiple myeloma” Leukemia 2008; 22: 1083. (IF 6,146)
81)
Gozzetti A, Calabrese S, Crupi R, Tozzuoli D, Fabbri A, Bocchia M, Pirrotta MT, Defina M,
Lauria F. Deletion 9q in a patient with concomitant myelodisplasia and non-Hodgkin lymphoma.
Cancer Genetic Cytogenetic 2007; 175 (2):177 . (IF 1,544)
82)
Gozzetti A, Cerase A, Tarantino A, Fabbri A, Bocchia M, Pirrotta MT, Lauria F. Multiple
myeloma involving the cavernous sinus: a report of 3 cases and response to bortezumib. Clin
Lymphoma Myeloma 2007; 7(5):376-8.
(IF 2,44)
83)
Pirrotta MT, Gozzetti A, Bucalossi A, Cerase A, Bocchia M, Defina M, Lauria F. Unusual
CNS and cutaneous involvements in multiple myeloma during bortezumib treatment. Onkologie
2008,; 31:45-47. (IF 1,724)
84)
Zaja F, Battista ML, Pirrotta MT, Calmieri S, Montagna M, Marini L, Cavallin M, Bocchia
M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzino MA, Ragazzi M, Fanin R. Low dose
rituximab shares similar activity but slower timimng of response than standard dose in patients with
immune thrombocytopenia. Hematologica 2008 93: 930 – 933. (IF 5,516)
85)
Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G,
Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M,
Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G. Chronic myeloid leukemia in blast
crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up (on behalf
of the GIMEMA Working Party on Chronic Myeloid Leukemia). Haematologica 2008; 93: 1792 –
1796. (IF 5,516)
86)
M Malagola, A Peli, D Damiani, A Candoni, M Tiribelli, G Martinelli, PP Piccaluga, S
Paolini, F De Rosa, F Lauria, M Bocchia, M Gobbi, I Pierri, A Zaccaria, E Zuffa, P Mazza, G
Priccolo, L Gugliotta, A Bonini, G Visani, C Skert, C Bergonzi, AM Roccaro, C Fili, R Fanin, M
Baccarani, and D Russo. Incidence of bacterial and fungal infections in newly diagnosed acute
myeloid leukaemia patients younger than 65 yr treated with induction regimens including
fludarabine: retrospective analysis of 224 cases. Eur J Haematol, Nov 2008; 81(5): 354-63.
(IF
2.163)
87)
Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia
M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G,
Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Collaborators (Bocchia M
and others). Results of high dose imatinib mesylate in intermediate Sokal risk chronic myeloid
leukemia patients in early chronic phase: a 2 trial of the GIMEMA CML working party. Blood
2009 113: 3428-34. (IF 10.896)
88)
Gozzetti A, Defina M, Bocchia M. Cutaneous myeloma and bortezumib. Ann Hematol.
2009 Oct;88(10):1045. Epub 2009 Jul 14.
(IF2.454)
89)
Gozzetti A, Crupi R, Defina M, Bocchia M, Raspadori D, Lauria F. Isolated deletion of 6q
in a patiente with myelodisplastic syndrome. Cancer Genet Cytogenet. 2009 Jul;192(1):51.
(I.F.1.482)
90)
Defina M, Rondoni M, Gozzetti A, Aprile L, Chitarrelli I, Fabbri A, Lauria F and Bocchia
M. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion. Br
J Haematol. 2010 Feb;148(3):483-4. Epub 2009 Oct 28.
(IF 4.597)
91)
Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M,
Tieghi A, Amadori S, Campagna S, Ferrara F, Battista ML, Angelucci E, Usala E, Cantoni S, Visani
G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Isola M, Soldano M, Gamba E, Fanin R.
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone
monotherapy in adults with primary immune thrombocytopenia. Blood 2010 115:2755-62. (I.F
10.896)
92)
Gozzetti A, Defina M, Bocchia M, Lauria F. Hyperlipidemic myeloma Ann Hematol. 2010
89 (9) :939-40. (IF 2.454)
93)
Gozzetti A, Crupi R, Rondoni M, Daviddi B, Defina M, Bocchia M, Pietrini A, Raspadori
D, Lauria F. Translocation (X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved
from essential thrombocytemia. Cancer Genet Cytogenet. 2010 1 Feb; 197 (1):84-5. (IF 1.482)
94)
Gozzetti A, Fabbri A, Oliva S, Marchini E, Bocchia M, Defina M, Lauria F. Weekly
bortezomib, pegylated liposomal Doxorubicin and dexamethasone is a safe and effective therapy fpr
elderly patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk, Feb
2010; 10(1): 68-72. (IF 1.596)
95)
Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A,
Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G, Martino B, Pierri I, Radaelli F,
Specchia G, Pane F, Saglio G, Rosti G and Baccarani M. The response to imatinib and interferonis more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphiapositive chronic myeloid leukemia patients in early chronic phase. Haematologica, 2010; 95: 1415 1419. (IF 6.416)
96)
Gozzetti A, Fabbri A, Defina M, Chitarrelli I and Bocchia M. Hyperlipidemia in a
myeloma patient after bortezomib treatment. Leuk Res 2010, 34: e250. (IF 2.390)
97)
Breccia M, Bocchia M, Cannella L, Defina M, Ippoliti G, Loglisci, Santopietro M, Lauria F
and Alimena G. Reduction of imatinib dose and persistence of complete molecular response after
p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired
resistance. Br J Haematol, 2010; 150(2): 240-2. (IF 4.597)
98)
Defina M, Gozzetti A, Rondoni M, Aprile L, Ippoliti M, Chitarrelli I, Lauria F, and Bocchia
M. Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic
response under imatinib. Leuk Res, 2010; 34(8): e215-6. (IF 2.390)
99)
Gozzetti A, Defina M, Bocchia M, Fabbri A, Marchini E, Chitarrelli I, and Lauria F. Safety
and efficacy of bortezumib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed
patients with multiple myeloma. Leuk Res, Nov 2010; 34 (11): e288-9. (IF 2.390)
100)
Gozzetti, R Crupi, M Rondoni, M Defina, M Bocchia, A Pietrini, D Raspadori, and F
Lauria. A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2. Acta
Haematol, Jan 2010; 124(1): 44-5.(IF 1.195)
101)
Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot A,
De Luca S, Ferrare F, Fanin R. Low-dose rituximab in adutl patients with primary immune
thrombocytopenia. Eur J Hematol 2010, 85(4): 329-34. (IF 2.345)
102)
Bocchia M, Defina M, Aprile L, Ippoliti M, Crupi R, Rondoni M, Gozzetti A, Lauria F.
Complete molecular response in CML after P210 BCR-ABL1-derived peptide vaccination. Nature
Rev Clinic Oncol Oct 2010. (I.F 8.075).
103)
Gozzetti A, Crupi R, Defina M, Bocchia M. Lenalidomide efficacy in bortezomib-resistant
myeloma. Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010 . (IF 8.075)
104)
Gugliotta G, Castagnetti F, Palandri P, Breccia M, Intermesoli T, Capucci A, Martino B,
Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I,
Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G,
Baccarani M, Rosti G, and on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto
CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age
on outcome, a survey by the GIMEMA CML Working Party. Blood 2011. 117:5591-5599. (IF
10.558)
105)
M Malagola, C Skert, M Vignetti, A Piciocchi, G Martinelli, G Alimena, C Mecucci, N
Testoni, I Iacobucci, M Clavio, M Gobbi, A Candoni, D Damiani, M Bocchia, F Lauria, A
Zaccaria, P Mazza, G Visani, A Peli, C Colombi, V Cancelli, M Mancini, R Fo, M Martelli, N
Cantore, FD Raimondo, M Petrini, P de Fabritiis, G Fioritoni, F Nobile, F Fabbiano, G Specchia, M
Baccarani, FL Coco, S Amadori, F Mandelli, and D Russo. A simple prognostic scoring system for
newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530
patients. Leuk Lymphoma 2011.(IF 2.492)
106)
A Gozzetti, G Coviello, A Fabbri, RD Corte, M Bocchia, M Defina, and F Lauria. Unusual
localization of plasmocytoma. Leuk Res 2011. 35(7): e104-5.(IF 2.555)
107)
A Gozzetti, A Cerase, R Crupi, D Raspadori, M Defina, M Bocchia, and F Lauria. A central
nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report.
Leuk Res 2011.(IF 2.555)
108)
Gozzetti A, Musto P, Defina M, D’Auria F, Papini G, Steduto T, D’Arena G, Bocchia M.
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell
leukaemia. British J Hematol. 2012 doi:10.1111/j.1365-2141.2012.09029.x (IF 4.597)
109)
Gozzetti A, Papini G, Defina M, Bocchia M. Extramedullary myeloma relapses.
Ann Hematol. 2012 Feb 25. [Epub ahead of print]. PMID:22362123
110)
Ippoliti M, Defina M, Gozzini A, Baratè C, Aprile L, Pietrini A, Gozzetti A, Raspadori D,
Lauria F, and Bocchia M. Identification of a Novel P190-Derived Breakpoint Peptide Suitable for
Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. Leukemia
Research and Treatment Volume 2012 (2012).
111)
Defina M, Ippoliti M, Gozzetti A, Abruzzese E, Castagnetti F, Crupi R, Tiribelli M, Breccia
M, Salvucci, Aprile L, Baratè C, Gozzini A, Rosti G, Lauria F and Bocchia M. Evaluation of
residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients in complete cytogenetic
response during first line nilotinib therapy. Cancer. 2012 Nov 1;118(21):5265-9. doi:
10.1002/cncr.27506. Epub 2012 Apr 19. (IF 5,131)
112)
Myeloid sarcoma and adenocarcinoma of the large bowel as collision tumors: a case report.
Rocca BJ, Ambrosio MR, Gozzetti A, Bocchia M, Leoncini L, Lazzi S. Histol Histopathol. 2012
Jul;27(7):941-7. PMID: 22648549 [PubMed - in process] (IF 2.480)
113)
Gozzetti A, Fabbri A, Pietrini A, Papini G, Cencini E, Frasconi A, Raspadori D, Defina M,
Lauria F, Bocchia M. Chemoimmunotherapy with Rituximab and low-dose oral fludarabine and
cyclophosphamide (R-FC-low dose os) as initial treatment for elderly patients with chronic
lymphocytic leukemia. Blood e-letter April 2012
114)
Gozzetti A, Cerase A, Defina M, Bocchia M. Eur J Haematol. Plasmacytoma of the skull.
2012 Apr;88(4):369. doi: 10.1111/j.1600-0609.2011.01714.x. Epub 2011 Nov 15. No abstract
available. (IF 2.614)
115)
Gozzetti A, Marchini E, Banchi B, Papini G, Defina M, Bocchia M, Lauria F.
Extramedullary multifocal plasmacytoma relapse in multiple myeloma. Leuk Res. 2012
Jan;36(1):e34-6. Epub 2011 Oct 10. No abstract available. (IF 2.923)
116)
Gozzetti A, Defina M, Bocchia M. Lenalidomide maintenance in myeloma. Nat Rev Clin
Oncol 2012 9:605. (IF 8,075)
117)
Gozzetti A, Rossi V, Cerase A, Papini G, Defina M, Bocchia M. Single agent lenalidomide
activity in multiple myeloma relapse evidenced uniquely by CT/PET. Mediterr J Hematol Infect Dis
2012; 4: e2012041. (IF 1,9)
118)
Fabbri A, Cencini E, Pietrini A, Gozzetti A, Defina M, Fontanelli G, Mazzei MA, Volterrani
L, Bocchia M. Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic
T-cell lymphoma: report of a case with long-term follow-up. Hematol Oncol. 2012 Nov 14. doi:
10.1002/hon.2038. [Epub ahead of print] PMID: 23161606 [PubMed - as supplied by publisher]
119)
Santilli F, Blardi P, Scarpini F, Acciavatto A, Ceccatelli L, Magliocca A, Avolio T, Bocchia
M, Scapellato C, Gioffrè WR, Auteri A, Ferracane SC, Puccetti. L. Genetic influence in liver
steatosis prevalence and proatherothrombotic/inflammatory profile in familial combined
hyperlipoproteinemia. International J of Cardiology. 2013 doi.org/10.1016. (IF 7,8)